RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation

BMC Cancer

Table 1 Correlation between RCC2 expression and clinicopathological features in lung cancer

Variables	Number	RCC2 expression				P value
Variables	Number	Low expression (−~−/+)		High expression (+~+++)		P value
Gender
Female	50	15	(30.0%)	35	(70.0%)	0.262^a
Male	152	59	(38.8%)	93	(61.2%)
Age
≤ 56	88	34	(38.6%)	54	(61.4%)	0.604^a
> 56	114	40	(35.1%)	74	(64.9%)
Type
Non-malignant^c	52	45	(86.5%)	7	(13.5%)	0.000^a
Malignant	120	14	(11.7%)	106	(88.3%)
Metastatic	30	15	(50.0%)	15	(50.0%)
Tissue
Lung	120	14	(11.7%)	106	(88.3%)	0.000^a
Lymph node	30	15	(50.0%)	15	(50.0%)
Pathology
Non-malignant	60	45	(75.0%)	15	(25.0%)	0.000^b
Adenocarcinoma	41	7	(17.1%)	34	(82.9%)
Squamous cell	40	8	(20.0%)	32	(80.0%)
Large cell	6	2	(33.3%)	4	(66.7%)
Others^d	50	8	(16.0%)	42	(84.0%)
Grade
1	27	4	(14.8%)	23	(85.2%)	0.278^a
2	19	2	(10.5%)	17	(89.5%)
3	25	7	(28.0%)	18	(72.0%)

“a” detected by Pearson’s χ² tests, “b” detected by continuity corrected χ² test. “c” non-malignant include 23 cases of normal lung, 19 cases of inflammation and 10 cases of benign tumor. “d” Others include 21 cases of small cell lung cancer 24 cases of bronchioloalveolar carcinoma and five cases of carcinoma sarcomatodes. Grade is only for non-small cell lung cancer

ISSN: 1471-2407